Pfizer Inc. (PFE) Q1 2018 Earnings Results

Pfizer Beats on EPS, Stock Down 3.31%

Pfizer's earnings report showed a slight beat on EPS, but the stock fell by 3.31% following the announcement. Investors may be concerned about the lack of revenue details and the absence of guidance, which could indicate uncertainty about future performance. The defensive tone from management suggests they are aware of challenges ahead, which may have contributed to the stock's decline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.77	N/A	+1.66%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding market conditions. They are prioritizing cost management while focusing on their product pipeline.

Management highlighted ongoing challenges in the market.

They emphasized a focus on cost management and operational efficiency.

Future growth will depend on pipeline developments.

Pfizer Beats on EPS, Stock Down 3.31%

Key numbers

Management commentary

Pfizer Inc.

More earnings this week

Pfizer Beats on EPS, Stock Down 3.31%

Key numbers

Management commentary